Меню
Набор скоро начнётся NCT07679789

Community-acquired Pneumonia Due to Chlamydia Pneumoniae

— Наблюдательное Community-Acquired Pneumonia

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Community-Acquired Pneumonia. Базовые параметры: Без ограничений · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Франция
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Prevalence and Phenotyping of Chlamydia Pneumoniae Infections Among Pnuemonias Tested With Simplex and Multiplex PCR

Обзор

This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include; 1. Outpatient management 2. Hospitalization in a medical ward 3. Admission to the intensive care unit 4. In-hospital mortality 5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP

Подробное описание

This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include;1)Outpatient management2)Hospitalization in a medical ward3)Admission to the intensive care unit4) In-hospital mortality5) Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6)Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP

Detailed Description We have all learned and continue to teach that community-acquired pneumonia (CAP) is essentially represented by three bacteria: Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae. While the recent Mycoplasma outbreak in France and the prevalence of severe Legionella infections in intensive care units confirm the real impact of these pathogens in CAP, the low number of Chlamydia pneumoniae cases documented by PCR raises questions.Over the past twenty years, the development of highly sensitive molecular tests (specific PCR or multiplex PCR targeting intracellular respiratory pathogens) has made it possible to precisely detect Chlamydia pneumoniae and to confirm or rule out its presence in the respiratory tract of patients with pneumonia.We are therefore conducting a retrospective study between France and Switzerland to determine, on the one hand, the number of CAP cases due to Chlamydia pneumoniae confirmed by PCR, and on the other hand, to better characterize the phenotype of these patients.

Первичные конечные точки

  • Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR [Срок оценки: January 2015 to December 2025]
Вторичные конечные точки (5)
  • Clinical Severity of Chlamydia pneumoniae Pneumonia [Срок оценки: From hospital admission through hospital discharge (up to 90 days)]
  • Radiological Characteristics [Срок оценки: Baseline (at the time of pneumonia diagnosis)]
  • Viral Co-Infection Rate [Срок оценки: Baseline (at the time of PCR testing)]
  • Bacterial Co-Infection Rate [Срок оценки: Baseline (at the time of PCR testing)]
  • Length of Hospital Stay [Срок оценки: From hospital admission through hospital discharge (up to 90 days)]

Критерии участия

Критерии включения

  • Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
  • Availability of clinical data allowing confirmation of pneumonia diagnosis.

Критерии исключения

  • Patient opposition to the use of medical data for research purposes.
  • Absence of pneumonia diagnosis.
  • Insufficient clinical data for analysis.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Другое

Центры проведения

Франция · 1 центр
  • Centre Hospitalier de Saint-Denis — Saint-Denis

Публикации

  • Garin N, Hugli O, Genne D, Greub G. Lack of Chlamydia-related bacteria among patients with community-acquired pneumonia. New Microbes New Infect. 2015 Oct 22;8:164-5. doi: 10.1016/j.nmni.2015.10.002. eCollection 2015 Nov. No abstract available. PMID 27257497
  • Garin N, Marti C, Skali Lami A, Prendki V. Atypical Pathogens in Adult Community-Acquired Pneumonia and Implications for Empiric Antibiotic Treatment: A Narrative Review. Microorganisms. 2022 Nov 24;10(12):2326. doi: 10.3390/microorganisms10122326. PMID 36557579
  • Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. Respir Investig. 2022 Jan;60(1):56-67. doi: 10.1016/j.resinv.2021.09.009. Epub 2021 Nov 5. PMID 34750083
  • Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006 May;12 Suppl 3:12-24. doi: 10.1111/j.1469-0691.2006.01393.x. PMID 16669925

Идентификаторы

NCT: NCT07679789 · 0079_MIR_CHLAMPAC

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗